A Study to Evaluate the Efficacy and Safety of Tasimelteon in Treating Sleep Disturbances in Individuals With Autism Spectrum Disorder
Latest Information Update: 26 Mar 2024
At a glance
- Drugs Tasimelteon (Primary)
- Indications Autistic disorder
- Focus Registrational; Therapeutic Use
- Sponsors Vanda Pharmaceuticals
- 19 Mar 2024 Planned End Date changed from 1 Jul 2023 to 1 Jul 2025.
- 19 Mar 2024 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2025.
- 29 Apr 2022 Status changed from planning to recruiting.